FDA reaffirms its oversight of press materials

Share this article:
FDA reaffirms its oversight of press materials
FDA reaffirms its oversight of press materials

The FDA issued a rare untitled letter concerning a pitch letter—a reminder that the agency does not consider press materials to be exempted from its oversight.

The target of the Oct. 31 letter was Cornerstone Therapeutics, which put out a press release for Curosurf, indicated for rescue treatment of premature infants experiencing Respiratory Distress Syndrome. The agency said the pitch letter was false and misleading due to omission of risk info and presentation of unsubstantiated superiority claims—standard objections. However, as the FDA Law Blog put it, “What makes this letter noteworthy is that the promotional materials complained about included a letter to the media pitching a story about Curosurf (a “pitch letter”) that included an attached press release.”

FDA has scrutinized press materials as a promotional tool in the past, notes Ilyssa Levins of the Center for Communication Compliance. Press materials were at the center of the wire fraud case around InterMune's Actimmune in 2008. CEO Scott Harkonen was sentenced to six months home confinement and a $20,000 fine in that cases.

“The letter is consistent with existing policy,” said Levins. “What's interesting is that regulatory compliance savvy for PR professionals has been an evolutionary process. The pitch letter is the last bastion of that.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?